Peter Nordkild
Chief Executive Officer at ASARINA PHARMA AB
Profile
Peter Nordkild is the founder of Adenium Biotech ApS (founded in 2011) and Arts Biologics A (founded in 2011).
He held the title of Chief Executive Officer at both companies.
His current job(s) include Chairman at K, Director at Dansk Biotek, Director at K, Director at K, Director at K, Director at Oracain ApS, Managing Director at PN Investment ApS, Director at Danish Biotech Association, and Chief Executive & Medical Officer at Asarina Pharma AB (since 2016).
His former job(s) include Chief Executive Officer at Egalet A (2010), Independent Director at Bioporto A (2013), Director at Ponticulus GmbH ApS, Medical Director at Squibb-Novo, Inc., General Manager-Austria Region at Novo Nordisk A (1998), Chief Financial & Commercial Officer at Pharmexa A (2009), Senior Vice President-Commercial Operations at Ferring Pharmaceuticals A, and External Consultant at Novo Ventures 1 A.
Peter Nordkild active positions
| Companies | Position | Start |
|---|---|---|
| ASARINA PHARMA AB | Chief Executive Officer | 2015-12-31 |
| K/S Asschenfeldt, Tyskland Super VIII | Director/Board Member | - |
| PN Investment ApS | Chief Executive Officer | - |
Oracain ApS
 Oracain ApS Pharmaceuticals: MajorHealth Technology Oracain ApS develops oral pain medications based on known active compounds. It is developing a novel pharmaceutical product for pain associated with oral mucositis and other complex conditions. The company was founded by Ove Andersen in 2011 and is headquartered in Lyngby, Denmark. | Director/Board Member | - |
| K/S Asschenfeldt, Tyskland Super II | Chairman | - |
| K/S Asschenfeldt, The Pentagon, Derby | Director/Board Member | - |
| K/S Asschenfeldt, Redcote Lane, Leeds | Director/Board Member | - |
| K/S Asschenfeldt, Lange Strasse, Delmenhorst | Chairman | 2012-07-24 |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Director/Board Member | 2010-05-24 |
| ░░░░░░ ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Peter Nordkild
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| BIOPORTO A/S | Health Technology |
| ASARINA PHARMA AB | Health Technology |
| Private companies | 17 |
|---|---|
Pharmexa A/S
 Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Health Technology |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Commercial Services |
| Ponticulus GmbH ApS | |
| K/S Asschenfeldt, Lange Strasse, Delmenhorst | |
| K/S Asschenfeldt, Redcote Lane, Leeds | |
| K/S Asschenfeldt, The Pentagon, Derby | |
| K/S Asschenfeldt, Tyskland Super II | |
| K/S Asschenfeldt, Tyskland Super VIII | |
Adenium Biotech ApS
 Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Oracain ApS
Oracain ApS Pharmaceuticals: MajorHealth Technology Oracain ApS develops oral pain medications based on known active compounds. It is developing a novel pharmaceutical product for pain associated with oral mucositis and other complex conditions. The company was founded by Ove Andersen in 2011 and is headquartered in Lyngby, Denmark. | Health Technology |
| Arts Biologics A/S | |
| PN Investment ApS | |
Egalet A/S
 Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | Health Technology |
| Squibb-Novo, Inc. | |
| Danish Biotech Association |
- Stock Market
- Insiders
- Peter Nordkild
